Research programme: orphan nuclear receptor antagonists - Orphagen Pharmaceuticals

Drug Profile

Research programme: orphan nuclear receptor antagonists - Orphagen Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); Orphagen Pharmaceuticals
  • Developer Orphagen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Cushing syndrome; Sickle cell anaemia
  • No development reported Anxiety disorders; Depressive disorders; Dry age-related macular degeneration; Endometriosis; Retinitis pigmentosa; Sleep disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Anxiety-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Depressive disorders in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Dry age-related macular degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top